Hematopoietic Stem Cell Donors' Experiences of Information and Side‐Effects During the First Year After Donation—A Swedish National Study
Journal of Clinical Apheresis · 2025
DOI: 10.1002/jca.70050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Apheresis, 2025. Verfasst von Annika M Kisch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Tissue Donors, Blood Donors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Swedish Blood cancer Society, The Swedish Cancer Society (in Swedish: Cancerfonden), Lions Cancer research in Uppsala.
Abstract (Originalsprache)
The aim was to describe hematopoietic stem cell (HSC) donors' experiences focusing on information and side effects during the first year after donation. Our prospective Swedish cohort study with adult HSC donors was performed from 2019 to 2022, with questionnaires at four time points from before until 12 months after donation. 173 unrelated and 68 related donors participated, and the majority donated peripheral blood stem cells. All but one rated their donation experience as good or very good. At least one side effect was reported by 83% of participants. Six donors (2.5%) experienced either numerous side effects, at least one severe side effect, or prolonged side effects. Satisfaction with information was lower among donors having severe side effects and bone marrow donors. Overall satisfaction with the donation was lower among donors having severe side effects and unrelated donors. Donors were generally satisfied with the pre‐donation information. Most experienced side effects that resolved within 2 weeks, which strengthens the case for unchanged donor follow‐up 1 month after donation, with individualized follow‐up for donors with persistent symptoms. Enhanced information regarding the risk of more severe or prolonged side effects appears warranted, and its effect on donor satisfaction should be evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
- Institute of Health Sciences, Lund University, Lund, Sweden.
- Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
- Medical Unit HHLH, Comprehensive Cancer Centre, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medical Sciences, Unit of Haematology, Uppsala University, Uppsala, Sweden.
- Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Sweden.
ORCID-Profile: Annika M Kisch, Jeanette Winterling, Hans Hägglund, Gunnar Larfors, Stig Lenhoff, Simon Pahnke
Förderung
- The Swedish Blood cancer Society
- The Swedish Cancer Society (in Swedish: Cancerfonden)
- Lions Cancer research in Uppsala
- The Foundation of the Oncology clinic research in Uppsala
Zitieren
APA
Kisch, A. M., Winterling, J., Hägglund, H., Larfors, G., Lenhoff, S., & Pahnke, S. (2025). Hematopoietic Stem Cell Donors' Experiences of Information and Side‐Effects During the First Year After Donation—A Swedish National Study. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70050
Vancouver
Kisch AM, Winterling J, Hägglund H, Larfors G, Lenhoff S, Pahnke S. Hematopoietic Stem Cell Donors' Experiences of Information and Side‐Effects During the First Year After Donation—A Swedish National Study. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70050
BibTeX
@article{Kisch2025,
author = {Kisch, Annika M and Winterling, Jeanette and Hägglund, Hans and Larfors, Gunnar and Lenhoff, Stig and Pahnke, Simon},
title = {Hematopoietic Stem Cell Donors' Experiences of Information and Side‐Effects During the First Year After Donation—A Swedish National Study},
journal = {Journal of Clinical Apheresis},
year = {2025},
doi = {10.1002/jca.70050}
}
EUVIMED